Europe's share in the global anti-infective market funds is 26% of antibacterial drugs - 25%, anti-virus - 33%, an antifungal - 25%. Japan market anti-infective, antibacterial, antiviral and antifungal agents covering 30, 32, 17 and 30% respectively [16]. First place in the world by sales of prescription drugs in the first half of 1999 took the company «Merck & Co.»: More than $ 8 billion (19% increase compared to c the same period in 1998). Second place at «Pfizer» - 7,7 billion (21% increase), y «GlaxoWellcome» - third place (Table 3). Significant growth of the company «Pfizer» were associated with the drug for the treatment of erectile dysfunction Viagra (sildenafil), with sales only in the second quarter of 1999 increased by 61%. Growth «GlaxoWellcome» hindered decrease in sales volumes of the drug Zantac (ranitidine) by 19% due to expiration of patent protection on the active ingredient of this drug. Company «Bristol-Myers Squibb» remained in fourth place, and the company «Roche» fifth place. Success of the company «Roche» contributed explosively increasing demand for the drug for the correction of overweight Xenical (orlistat), as well as growth in sales of other innovative products that are used to prevent kidney transplant rejection, such as CellCept (micophenolate mofetil) and Zenapax (daclizumab) . Company «Johnson & Johnson» (sixth place) showed the greatest growth in sales in the first half of 1999 - 22%. Company «Novartis», despite the fact that the rating it has moved two places down, showed a positive growth trend in sales of pharmaceutical products from 1% in the first half of 1998 to 5% in the first half of 1999 global trend "domination" of the largest manufacturers of original products is not typical for the Russian market, where sales volumes lead mostly generic companies (in 1999, according to RMBC, first among foreign manufacturers took the company «Gedeon Richter»). The share of the largest manufacturers of drugs, such as corporations «Merck & Co.», "Novartis", the global market does not exceed 5%. At the same time, the situation in the pharmaceutical business develops in such a way that only the integration can enable companies to survive and grow in the face of fierce competition and high growth rates for spending on research and development, which at some firms is higher than the growth in sales volumes. Examples of major mergers announced in 1998 and ended in 1999, was a merger «Rhone Poulenc Rorer» and «Hoechst Marion Roussel» with the formation of the company «Aventis»; «Astra» and «Zeneca» - of «AstraZeneca»; «Sanofi» and «Synthelabo» - of «Sanofi-Synthelabo». The merger of major international pharmaceutical companies and the formation of mega-corporations today is especially important. Firstly, according to forecasts of most analysts, in the next 5-10 years in the world of pharmacy is expected developments of the crisis - now existing drugs will be included in the downward phase of the life cycle, when the volume of their sales will decline gradually, and scientific laboratories belonging to the manufacturing companies as well as independent biotech firm, yet not be able to offer the market a radically new medicines.
No comments:
Post a Comment